NuCana (NASDAQ:NCNA – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer in a research note issued on Monday, Benzinga reports. They presently have a $150.00 price objective on the stock.
NuCana Price Performance
NCNA stock traded up $0.09 during mid-day trading on Monday, reaching $3.59. The company had a trading volume of 35,835 shares, compared to its average volume of 42,056. The company has a market capitalization of $9.49 million, a PE ratio of -0.31 and a beta of 0.99. The firm has a 50 day moving average of $3.15 and a 200 day moving average of $4.97. NuCana has a 12 month low of $2.53 and a 12 month high of $20.25.
NuCana (NASDAQ:NCNA – Get Free Report) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.31) by $3.15. Analysts anticipate that NuCana will post -11.79 EPS for the current year.
Institutional Inflows and Outflows
About NuCana
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Featured Stories
- Five stocks we like better than NuCana
- What to Know About Investing in Penny Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What Do S&P 500 Stocks Tell Investors About the Market?
- 2 Option Strategies to Maximize Profits in a Bear Market
- The 3 Best Retail Stocks to Shop for in August
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.